链杆菌分离了SOM013,这是对抗微生物耐药性和胃的潜在药物
Kizito Eneye Bello1, Ahmad Adebayo Irekeola2,3, Ahmad A Alshehri4,5
1Department of Microbiology, Faculty of Natural Science, Kogi State (Prince Abubakar Audu) University, Anyigba, PMB 1008, Anyigba, Kogi State, Nigeria.
概括
一个新的Streptomyces分离物,SOM013,显示出作为新抗生素和抗治疗的来源的希望. 它的提取物在动物模型中表现出显著的抗微生物活性对抗耐药细菌和强大的抗效应.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 抗微生物耐药性的上升和再次出现的传染病需要新的治疗药物.
- 杆菌 (Streptomyces) 种类是生物活性天然产品的成熟来源,包括抗生素.
研究的目的:
- 为了研究一种特定的Streptomyces分离物的抗微生物和抗活动,SOM013.
- 评估SOM013二次代谢物的潜力,作为对抗耐药病原体和胃的治疗剂.
主要方法:
- 隔离和净化Streptomyces spp. 的方法. 来自环境样本.
- 用甲醇和水发酵分离物SOM013并提取二次代谢产物.
- 对抗耐药性细菌和真菌的小组进行抗微生物敏感性测试.
- 在动物中使用甲醇诱导的胃模型对抗的活性进行评估.
主要成果:
- SOM013的甲醇提取物对经过测试的耐药微生物表现出强烈的抗菌活性,具有显著的剂量依赖作用.
- 提取物显示了对抗抗扩展-宽谱耐药性Pseudomonas aeruginosa的最高抑制区域.
- SOM013提取物表现出显著的剂量依赖性抗活性,降低了指数并增加了保护功效.
结论:
- 单独的Streptomyces SOM013产生了具有中度抗微生物和高抗活性的代谢物.
- 这些发现表明,SOM013是进一步药理学探索和新药开发的有希望的候选者.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
368
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
368
01:26Peptic Ulcer Disease IV: Management
88
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
88
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
408
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
408
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
111
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
111
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
446
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
446
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
380
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
380